PubRank

A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

Clinical Trial ID NCT00943826

PubWeight™ 47.90‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00943826

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014 9.09
2 Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2010 4.23
3 Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol 2015 3.24
4 Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol 2015 2.97
5 Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011 1.38
6 Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011 1.29
7 Recent advances in the molecular understanding of glioblastoma. J Neurooncol 2012 1.29
8 Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int 2012 1.23
9 Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010 1.23
10 Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol 2010 1.19
11 Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol 2012 1.16
12 Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013 1.16
13 Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med 2011 1.07
14 Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 2010 1.06
15 Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015 1.06
16 Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010 1.05
17 Novel therapies in glioblastoma. Neurol Res Int 2012 0.97
18 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015 0.92
19 Unique biology of gliomas: challenges and opportunities. Trends Neurosci 2012 0.87
20 New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther 2010 0.83
21 Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 2011 0.83
22 The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother Pharmacol 2012 0.82
23 Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist 2013 0.81
24 Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 2015 0.81
25 Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol 2016 0.81
26 Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 2016 0.80
27 Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol 2016 0.80
28 Is there a role for bevacizumab in the treatment of glioblastoma? Oncologist 2013 0.79
29 Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. J Neurooncol 2013 0.79
30 Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. Expert Opin Pharmacother 2014 0.79
31 Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro Oncol 2016 0.78
32 Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS One 2016 0.78
33 Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 2016 0.77
34 Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol 2015 0.77
35 Neurosurgery Concepts: Key perspectives on Traumatic Brain Injury, New Treatments for Glioblastoma, Hemicraniectomy for Extensive Middle-Cerebral-Artery Stroke, Minimally Invasive Spine Surgery and Lumbar Epidural Injections for Radiculopathy. Surg Neurol Int 2015 0.75
Next 100